Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06632236 |
Title | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) |
Acronym | 5G-EMERALD |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Institute of Cancer Research, United Kingdom |
Indications | |
Therapies | |
Age Groups: | child | senior | adult |
Covered Countries | GBR |